Slovenian Guidelines for the Management of Multiple Myeloma 2015
Abstract
Multiple myeloma is the second most common hematologic malignancy in western world. There are every year around 120 newly diagnosed patients in Slovenija and their survival is on the path of sustained improvement. After year 2006, we are presenting new 2015 uptodated new slovenian guidelines, dealing with diagnostics and treatment of multiple myeloma.
Downloads
References
Mlakar U, Andoljšek D, Fikfak N, Glaser M, Grat M, Grmek-Zemljič T, et al. Smernice za odkrivanje in zdravljenje diseminiranega plazmocitoma. Zdrav Vestn. 2006;75:3-8.
Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7.
Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb;99(2):232-42.
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 9;117(23):6063-73.
Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, et al. European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist. 2014 Aug;19(8):829-44.
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan;78(1):21-33.
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11;116(19):3724-34.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24.
Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001 Dec;68(4):269-75.
Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O'Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012 Aug;97(8):1272-7.
Pianko MJ, Terpos E, Roodman GD, Divgi CR, Zweegman S, Hillengass J, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res. 2014 Dec 1;20(23):5888-97.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun;24(6):1121-7.
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Mar 30;354(13):1362-9.
The International Myeloma Worling Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun;121(5):749-57.
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90.
Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. Aug 1;369(5):438-47.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5;117(18):4691-5.
Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20;32(6):587-600.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-e48.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77.
Cavo M, Salwender H, Rosinol L. Double versus single autologous stem cell transplantation after bortezomib based induction regimns for multiple myeloma: an integral analysis of patient level datafrom phase III European studise. Blood 2013, 122: 767a.
San Miguel J, Weisel K, Morreau P. Pomalidomide plus low dose dexamethason versus high dose dexamethason alone for patients with relapsed or refractory multiple myeloma: a randomised open label phase III trial. Lancet Oncol 2013: 14: 1055-66.
Leleu X, Karlin L, Macro M. Pomalidomide plus low dose dexametasone in relapsed or refractory MM with del17 and/or translocation (4;14). Blood 2013; 122: 689a.
Sonneveld P, Goldschmidt H, Rosinol L. Bortezomib based versus non-bortezomib based induction treatment before autologous SCT in patients with previously untreated MM : a meta analysis of phase III randomised, controlled trials. J Clin Oncol 2013; 31: 3279-87.
Leiba M, Kedmi M, Duek A, Friedman T, Weiss M, Leiba R. Bortezomib-Cyclophosphamide. Dexametasone versus Bortezomib-Thalidomide Dexametasone based regimens as induction therapies in newly diagnosed transplant eligible patients with MM: a meta analysis. British J Haematol 2014; 166: 702-710.
Costa LJ, Nista EJ, Buadi FK. Prediction of poor mobilisation of autologous CD34+ cells with growth factorin multiple myeloma patients: implications for risk stratifications: Biol Blood Marrow Transplant 2014; 20(2): 222-28.
Kumar SK, Lacey MQ, Dispanzieri A. Early versus delayed autologous transplantation after immunomodulatory based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012; 118: 1585-92.
Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 2014; 124(6): 822-90.
Jimenez-Zapeda VH, Mikhael J, Winter A. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression free survival and overall survival, Biol Blood Marrow Transplantation 2012; 18: 773-79.
Attal M, Harosseau JL, Facon T. IGFM single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349(269): 2495-2502.
Kumer A, Kharfan- Dabaja MA, Glasmacher A, Djulbegović B. Tandem versus single autologous HSCT for treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 10(2): 100-106.
Gay F, Cavallo F, Caravita F. Maintanance therapy with lenalidomide significantely improved survival of young newly diagnosed multiple myeloma patients. Blood 2013; 122: 2089a.
Morgan GJ, Davies FE, Gregory FE. Long term follow up of MRC Myeloma trial IX: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013; 19: 6030-38.
Cook G, Liakopoulou E, Pearce R. Factors influencing the outcome of the second ASCT in relapsed multiple myeloma: a study from the british society of blood and marrow transplantationregistry. Biol Blood Marrow Transpl2011; 17: 1638-45.
Yhim HY, Kim K, Kim JS. Matched pair analysisto compare the outcomes of the second salvage auto HSCT to systemic chemotherapy alone in patiets with MM who relapsed after front line auto HSCT. Bone Marrow Transpl 2013; 48(3): 425-32.
Atanackovic D, Schilling G. Second autologous transplant as salvage therapy in MM. Br J Haematol 2013; 163(5): 565-72.
Giaccone L, Storer B, Ptariarca F. Long term follow up of a nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011, 117: 6721-27.
Bringhen S, Mateos MV, Zweegmann S. Ageand organe damage correlate with poor survival in myeloma patients: a meta-analysis of 1435 individual patient data from 4 randomised trials. Haematologica 2013; 98: 980-987.
San Miguel J, Schlag R, Kuagheva NK, Dimopoulos M. Botezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
Mateos MV, Oriol A, Lopez JM, Teruel AI, Guia AL, loppez E. GEM 2005 trial update comparing VMP/VTPas induction in elderly multiple myeloma patients: do we still need anlkylators ? Blood 2014; 124(12): 1887-94.
Benboubker L, Dimopoulos M, Dispanzieri A. Catalano J, Belch AR, Cavo M, Pinto, A, Weisel K. Lenalidomide and dexamethasone in transplant ineligible patiets with myeloma. N.Engl J Med 2014; 371(10): 906-17.
Knopf KB, Duh MS, Lafauille MH. Meta-analysis of the efficacy and safety of bortezomib retreatment in patients with multiple myeloma. Leuk 2013, 13(suppl 1):P-228a.
Dimopoulus MA, Petrucci MT, Foa R. Analysis of lenalidomide second line following initial relapse in MM-015 trial. Blood 2012; 120: 944a.
Mhaskar R, Redzepovic J, Wheatley K. Bisphosphonates in multiple mieloma: a network meta-analysis. Cochrane database Syst Rev 2012; 5: CD003188.
Morgan GJ, Davies FE, Gregory WM. First line treatment with zolendronic acid compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-99.
Zervas K, Verrou E, Teleioudis Z. Incidence, risk factors and management of osteonecrosis of the jaw in patiets with multiple myeloma; a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620-23.
Henry DH, Costa L, Goldwasser L, Hirsh V, Hungria V, Prausova J. Randomised double blind study of denosumab versus zolendronic acid in the treatment of bone metastasis with advanced cancer or multiple myeloma. J Clin Oncol 2011; 29(9): 1125-32.
Palumbo A, Anderson K. Medical progress: Multiple myeloma. N Engl J Med 2011; 364: 1046-60.
Palumbo A. Cavo M, Bringhen S, Zamagni E, Romano A. Patriarca F. Aspirin, warfarin or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III open label randomised trial. J Clin Oncol 2011; 29(8): 986-93.
Engelhardt M, Wasch R, Landgreen O, Kleber M. Multiple myeloma and secondary malignancies. Clin Lymphoma Myeloma Leuk 2014; 14(2): 98-101.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
